Search

Your search keyword '"Emi H Caywood"' showing total 6 results
Start Over Author "Emi H Caywood" Topic hematology
6 results on '"Emi H Caywood"'

1. Excellent Relapse-Free and Overall Survival in Pre-HCT Next-Generation Sequencing (NGS-MRD) Negative B-ALL Patients with or without TBI-Based Conditioning: Outcome of the Observational Arm of the Pediatric Transplantation and Cellular Therapy Consortium (PTCTC) ONC1701 Endrad Study

Author

Hisham Abdel-Azim, Troy C. Quigg, Jemily Malvar, Elizabeth Gourdine, Neena Kapoor, Amy K. Keating, Kris Michael Mahadeo, Jodi L. Skiles, Dana Salzberg, Lisa M. Madden, Rachel Phelan, Nahal Lalefar, Emi H. Caywood, Rabi Hanna, Shalini Shenoy, Heather E. Stefanski, Biljana Horn, Benjamin Oshrine, Christine S. Higham, Ulrich A. Duffner, Joseph H. Chewning, Jason Law, Niketa C. Shah, Jeffrey S. Huo, Leslie E. Lehmann, Ibrahim Ahmed, Barbara Bambach, and Michael A Pulsipher

Subjects
Transplantation, Molecular Medicine, Immunology and Allergy, Cell Biology, Hematology
Published
2023

2. Prospective PTCTC Trial of Myeloablative HaploBMT with Post-transplant Cyclophosphamide for Pediatric Acute Leukemias

Author

Juan Carlos Fierro-Pineda, Hua-Ling Tsai, Amanda L Blackford, Andrew Cluster, Emi H Caywood, Jignesh Dalal, Jeffrey H Davis, R. Maarten Egeler, Jeffrey Huo, Michelle Hudspeth, Amy K. Keating, Susan S Kelly, Joerg Krueger, Dean A Lee, Leslie Elaine Lehmann, Lisa Madden, Benjamin R Oshrine, Michael A Pulsipher, Terry J Fry, and Heather J Symons

Subjects
Hematology
Abstract

Promising results have been reported for adult patients with high-risk hematologic malignancies undergoing haploidentical bone marrow transplant (haploBMT) with post-transplantation cyclophosphamide (PTCy). We report results from the first multicenter trial for pediatric and young adult patients with high-risk acute leukemias and myelodysplastic syndrome (MDS) in the US and Canada in the Pediatric Transplantation and Cellular Therapy Consortium (PTCTC). Nine centers transplanted 32 patients with acute leukemias or MDS with myeloablative conditioning (MAC), haploBMT with PTCy, mycophenolate mofetil, and tacrolimus. The median age was 12y (range 1-23y). Diagnoses included acute myeloid leukemia (n=15), acute lymphoid leukemia (n=11), mixed lineage leukemia (n=1), and MDS (n=5). Transplant-related mortality (TRM) at 180 days, our primary objective, was 0%. The cumulative incidence (CuI) of acute graft-versus-host disease (aGVHD) grade II at Day 100 was 13%. No patients developed aGVHD grades III-IV. The CuI of moderate-severe chronic GVHD (cGVHD) at 1 year was 4%. Donor engraftment occurred in 27/32 (84%). Primary graft failures included three patients that received suboptimal bone marrow grafts, all successfully engrafted after second transplants. The CuI of relapse at 1y was 32%, with more relapse in pre-BMT MRD+ versus MRD- patients. Overall survival at 1y and 2y is 77% and 73%, and event-free survival at 1y and 2y is 68% and 64%, respectively. We demonstrate no TRM or severe aGVHD, low cGVHD, and favorable relapse and survival rates. This successful pilot has led to a phase III trial comparing MAC haploBMT versus HLA-matched unrelated donors, now open in the Children's Oncology Group.

Published
2023

3. A diagnostic classifier for pediatric chronic graft-versus-host disease: results of the ABLE / PBMTC 1202 study

Author

Geoffrey D.E. Cuvelier, Bernard Ng, Sayeh Abdossamadi, Eneida R. Nemecek, Alexis Melton, Carrie L. Kitko, Victor Anthony Lewis, Tal Schechter, David A Jacobsohn, Andrew C. Harris, Michael A Pulsipher, Henrique Bittencourt, Sung Won Choi, Emi H Caywood, Kimberly A. Kasow, Monica Bhatia, Benjamin R Oshrine, Sonali Chaudhury, Donald Coulter, Joseph H Chewning, Michael Joyce, Süreyya Savaşan, Anna B Pawlowska, Gail C Megason, David Mitchell, Alexandra C Cheerva, Anita Lawitschka, Elena Ostroumov, and Kirk R Schultz

Subjects
Hematology
Abstract

The NIH Consensus Criteria for chronic graft-versus-host disease (cGVHD) diagnosis can be challenging to apply in children. We aimed to discover diagnostic pediatric cGVHD biomarkers that would complement clinical criteria and differentiate cGVHD from non-cGVHD diagnoses. The Applied Biomarkers of Late Effects of Childhood Cancer (ABLE) study (27 transplant centers) prospectively evaluated 302 pediatric patients after hematopoietic cell transplant (234 evaluable). Forty-four patients developed cGVHD. Mixed and fixed effect regression analyses were performed on diagnostic cGVHD onset blood samples for cellular and plasma biomarkers, with individual markers declared relevant if they met three criteria: an effect ratio ≥1.3 or ≤0.75; an area under the curve (AUC) of ≥0.60; and a p-value

Published
2022

4. Outcomes following treatment for ADA-deficient severe combined immunodeficiency: a report from the PIDTC

Author

Geoffrey D. E. Cuvelier, Brent R. Logan, Susan E. Prockop, Rebecca H. Buckley, Caroline Y. Kuo, Linda M. Griffith, Xuerong Liu, Alison Yip, Michael S. Hershfield, Paul G. Ayoub, Theodore B. Moore, Morna J. Dorsey, Richard J. O’Reilly, Neena Kapoor, Sung-Yun Pai, Malika Kapadia, Christen L. Ebens, Lisa R. Forbes Satter, Lauri M. Burroughs, Aleksandra Petrovic, Deepak Chellapandian, Jennifer Heimall, David C. Shyr, Ahmad Rayes, Jeffrey J. Bednarski, Sharat Chandra, Shanmuganathan Chandrakasan, Alfred P. Gillio, Lisa Madden, Troy C. Quigg, Emi H. Caywood, Blachy J. Dávila Saldaña, Kenneth DeSantes, Hesham Eissa, Frederick D. Goldman, Jacob Rozmus, Ami J. Shah, Mark T. Vander Lugt, Monica S. Thakar, Roberta E. Parrott, Caridad Martinez, Jennifer W. Leiding, Troy R. Torgerson, Michael A. Pulsipher, Luigi D. Notarangelo, Morton J. Cowan, Christopher C. Dvorak, Elie Haddad, Jennifer M. Puck, and Donald B. Kohn

Subjects
Adenosine Deaminase, Agammaglobulinemia, Child, Preschool, Immunology, Hematopoietic Stem Cell Transplantation, Infant, Newborn, Humans, Infant, Severe Combined Immunodeficiency, Cell Biology, Hematology, Biochemistry
Abstract

Adenosine deaminase (ADA) deficiency causes ∼13% of cases of severe combined immune deficiency (SCID). Treatments include enzyme replacement therapy (ERT), hematopoietic cell transplant (HCT), and gene therapy (GT). We evaluated 131 patients with ADA-SCID diagnosed between 1982 and 2017 who were enrolled in the Primary Immune Deficiency Treatment Consortium SCID studies. Baseline clinical, immunologic, genetic characteristics, and treatment outcomes were analyzed. First definitive cellular therapy (FDCT) included 56 receiving HCT without preceding ERT (HCT); 31 HCT preceded by ERT (ERT-HCT); and 33 GT preceded by ERT (ERT-GT). Five-year event-free survival (EFS, alive, no need for further ERT or cellular therapy) was 49.5% (HCT), 73% (ERT-HCT), and 75.3% (ERT-GT; P < .01). Overall survival (OS) at 5 years after FDCT was 72.5% (HCT), 79.6% (ERT-HCT), and 100% (ERT-GT; P = .01). Five-year OS was superior for patients undergoing HCT at

Published
2022

5. Outcomes after Hematopoietic Cell Transplant and Gene Therapy for Adenosine Deaminase (ADA) Severe Combined Immune Deficiency: A Combined Analysis from the Primary Immune Deficiency Treatment Consortium (PIDTC) 6901 and 6902 Studies

Author

Geoff D.E. Cuvelier, Brent Logan, Susan E. Prockop, Rebecca H. Buckley, Caroline Y. Kuo, Linda M. Griffith, Xuerong Liu, Alison Yip, Michael S. Hershfield, Roberta E Parrott, Christen L. Ebens, Theodore B. Moore, Richard J. O’Reilly, Sung-Yun Pai, Malika Kapadia, Neena Kapoor, Lisa R. Forbes Satter, Caridad Martinez, Lauri M. Burroughs, Aleksandra Petrovic, Monica S. Thakar, Deepak Chellapandian, Jennifer Heimall, David C. Shyr, Ahmad Rayes, Jeffrey J. Bednarski II, Sharat Chandra, Shanmuganathan Chandrakasan, Alfred P. Gillio, Lisa Madden, Troy C. Quigg, Emi H. Caywood, Blachy J Dávila Saldaña, Kenneth DeSantes, Hesham Eissa, Frederick Goldman, Jacob Rozmus, Ami J Shah, Mark T. Vander Lugt, Mike A. Pulsipher, Luigi D. Notarangelo, Morton J. Cowan, Christopher C. Dvorak, Elie Haddad, Jennifer Puck, and Donald B. Kohn

Subjects
Transplantation, Molecular Medicine, Immunology and Allergy, Cell Biology, Hematology
Published
2022

6. Relapse Risk for B-ALL Patients By Pre-Hematopoietic Cell Transplantation (HCT) Next-Generation Sequencing (NGS-MRD): An Interim Analysis of Observational Arm Subjects on Pediatric Transplantation and Cellular Therapy Consortium (PTCTC) ONC1701

Author

Troy C. Quigg, Jodi L. Skiles, Amy K. Keating, Kris M Mahadeo, Dana Salzberg, Lisa M. Madden, Rachel Phelan, Nahal Lalefar, Emi H. Caywood, Rabi Hanna, Sima T. Bhatt, Heather E. Stefanski, Biljana Horn, Benjamin Oshrine, Christine S. Higham, Ulrich A. Duffner, Joseph H. Chewning, Jason Law, Niketa C. Shah, Jeffrey S. Huo, Leslie E. Lehmann, Ibrahim Ahmed, Michael A. Pulsipher, and Hisham Abdel-Azim

Subjects
Transplantation, Molecular Medicine, Immunology and Allergy, Cell Biology, Hematology
Published
2022

Catalog

Books, media, physical & digital resources
See catalog results